NASDAQ:VRPX Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis → Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free VRPX Stock Alerts $0.70 -0.03 (-4.11%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.65▼$0.7350-Day Range$0.70▼$4.2652-Week Range$0.63▼$11.77Volume65,983 shsAverage Volume225,571 shsMarket Capitalization$819,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Virpax Pharmaceuticals alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Read More VRPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRPX Stock News HeadlinesMay 30 at 6:54 AM | americanbankingnews.comShort Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 907.6%May 29, 2024 | businesswire.comVirpax® Pharmaceuticals to Present at 2024 BIO International ConventionMay 23, 2024 | msn.comMaxim Group Downgrades Virpax Pharmaceuticals (VRPX)May 23, 2024 | americanbankingnews.comMaxim Group Reaffirms Hold Rating for Virpax Pharmaceuticals (NASDAQ:VRPX)May 18, 2024 | uk.investing.comVirpax Pharmaceuticals sets terms for $2.25 million offeringMay 16, 2024 | wsj.comVirpax Pharmaceuticals Inc.May 15, 2024 | marketwatch.comVirpax Pharmaceuticals Shares Hit All-Time Low After Equity SaleMay 15, 2024 | investorplace.comWhy Is Virpax Pharmaceuticals (VRPX) Stock Down 61% Today?May 15, 2024 | businesswire.comVirpax Announces Pricing of $2.25 Million Public OfferingMay 14, 2024 | investorplace.comVRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q1 2024May 13, 2024 | businesswire.comVirpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsMay 8, 2024 | msn.comVirpax Pharmaceuticals' Probudur Shows Promising Results in Pain Management StudyApril 30, 2024 | businesswire.comVirpax Announces Results of Maximum Tolerated Dose Study for Probudur™April 24, 2024 | investorplace.comVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023April 2, 2024 | msn.comVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management SolutionsMarch 26, 2024 | businesswire.comVirpax Pharmaceuticals Reports 2023 Year-End ResultsFebruary 27, 2024 | finance.yahoo.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceFebruary 27, 2024 | businesswire.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 12, 2024 | msn.comVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot StudyFebruary 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)February 7, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)January 23, 2024 | investing.comVirpax Pharmaceuticals Inc (VRPX)December 29, 2023 | msn.comVirpax Pharmaceuticals shareholders okay reverse stock splitDecember 28, 2023 | msn.comTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitSee More Headlines Receive VRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/02/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VRPX CUSIPN/A CIK1708331 Webwww.virpaxpharma.com Phone610-727-4597FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-345.87% Return on Assets-161.82% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.04) per share Price / Book-0.67Miscellaneous Outstanding Shares1,170,000Free Float1,098,000Market Cap$819,000.00 OptionableNot Optionable Beta1.56 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gerald W. Bruce (Age 67)CEO & Director Comp: $371.87kMr. Vinay Shah A.C.A. (Age 61)M.B.A., CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary Comp: $238kDr. Sheila A. Mathias J.D. (Age 56)M.B.A., Ph.D., Chief Scientific Officer Comp: $698.97kMs. Shana PanzarellaChief of StaffKey Competitors60 Degrees PharmaceuticalsNASDAQ:SXTPSonoma PharmaceuticalsNASDAQ:SNOABio-PathNASDAQ:BPTHExicureNASDAQ:XCURSeelos TherapeuticsNASDAQ:SEELView All Competitors VRPX Stock Analysis - Frequently Asked Questions Should I buy or sell Virpax Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virpax Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VRPX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRPX, but not buy additional shares or sell existing shares. View VRPX analyst ratings or view top-rated stocks. How have VRPX shares performed in 2024? Virpax Pharmaceuticals' stock was trading at $3.2010 at the beginning of the year. Since then, VRPX shares have decreased by 78.1% and is now trading at $0.70. View the best growth stocks for 2024 here. Are investors shorting Virpax Pharmaceuticals? Virpax Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 79,600 shares, an increase of 907.6% from the April 30th total of 7,900 shares. Based on an average daily trading volume, of 90,300 shares, the short-interest ratio is currently 0.9 days. Approximately 5.1% of the shares of the company are sold short. View Virpax Pharmaceuticals' Short Interest. When is Virpax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our VRPX earnings forecast. When did Virpax Pharmaceuticals' stock split? Shares of Virpax Pharmaceuticals reverse split on Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virpax Pharmaceuticals IPO? Virpax Pharmaceuticals (VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virpax Pharmaceuticals? Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRPX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
